Last updated: February 25, 2026
Case Overview
AbbVie Inc. filed suit against Hetero Labs Limited on February 4, 2025. The complaint (1:25-cv-00625) centers on patent infringement claims related to AbbVie's blockbuster drug, Humira (adalimumab). The case is filed in the District of Delaware, a frequent venue for pharmaceutical patent disputes.
AbbVie asserts that Hetero's production and sale of biosimilar versions of Humira infringe on multiple patents held by AbbVie. The patents in question include U.S. Patent Nos. 8,916,157 and 9,982,149, which cover formulations, methods of use, and manufacturing processes of Humira.
Patent Claims and Allegations
AbbVie claims that Hetero's biosimilar products infringe on the '157 and '149 patents, which expired in 2027 and 2028 respectively, but are still enforceable under U.S. patent law. The patents claim methods of reducing immunogenicity and maintaining drug stability, critical for biosimilar development.
AbbVie also argues that Hetero's biosimilar application, submitted to the FDA under BLA 761231, infringes on these patents through its manufacturing process and proposed indications for rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.
Legal Actions and Procedural Posture
- Infringement Allegations: The complaint alleges direct infringement, inducement, and contributory infringement.
- Preliminary Injunction: AbbVie seeks an injunction to prevent Hetero from marketing or selling the biosimilars before the patent expiry.
- Claim Construction: The court scheduled a Markman hearing for May 2025 to interpret key patent claim language.
- Summary Judgment: Hetero has filed a motion for summary judgment on multiple patents’ validity, arguing that prior art invalidates the claims or they fail to meet patentable subject matter standards.
Key Legal Issues
Patent Validity
Hetero contends that the patents are invalid due to obviousness and lack of non-obviousness in light of prior art references, including international biosimilar patents filed by Sandoz and Samsung Bioepis.
Patent Term and Pediatric Extensions
AbbVie asserts the patents are valid extensions of existing patent rights, compensating for regulatory delays, and maintains the patents' enforceability until 2027-2028.
Patent Infringement
The core issue is whether Hetero’s biosimilar products infringe on claims covering manufacturing processes and formulations, specifically related to immunogenicity reduction and stability methods.
FDA Regulatory Status
Hetero's biosimilar application is under FDA review, with an approval decision pending. The outcome may influence the scope of patent enforcement.
Historical Context and Industry Impact
AbbVie’s patent portfolio for Humira is among the most extensive in biotech, with over 70 patents related to the drug. Patent litigation has historically delayed biosimilar entry in the U.S. market, with AbbVie using patent thickets to deter early competition.
The case echoes prior patent disputes involving biosimilars from Amgen and Samsung Bioepis, where courts scrutinized patent validity, especially concerning method patents versus product patents.
Market and Business Implications
- Biosimilar Launch Delays: If AbbVie secures an injunction, Hetero will face market delays, impacting revenue projections for biosimilars expected to enter by 2025.
- Patent Litigation Duration: Patent disputes typically last 2-3 years; the outcome could influence Hetero’s timeline for commercial sale.
- Settlement Potential: Parties may resolve via license or settlement, as seen in prior biosimilar patent cases.
Critical Deadlines and Next Steps
| Date |
Event |
Impact |
| May 2025 |
Markman hearing |
Claim construction ruling |
| August 2025 |
Fact discovery completion |
Evidence gathering concludes |
| November 2025 |
Expert disclosures |
Technical analysis submitted |
| January 2026 |
Summary judgment motions |
Legal questions resolved or narrowed |
| Mid-2026 |
Trial date (potential) |
Final adjudication |
Comparative Analysis
| Aspect |
AbbVie |
Hetero |
Industry Average |
| Patent portfolio size |
70+ patents |
Challenging patents |
Varies significantly |
| Patent expiration |
2027-2028 |
Post-2025 biosimilar plans |
Typically 20-year patent term |
| Litigation duration |
Expected 2-3 years |
Similar |
Similar |
Summary of Legal Trends
- Courts are scrutinizing method patents more rigorously concerning obviousness.
- Patent extensions via pediatric or orphan drug designations are common but contested.
- Patent litigations influence biosimilar market entry timing significantly.
Key Takeaways
- The case reflects ongoing patent protection strategies by brand-name pharmaceutical holders.
- Validity of method patents remains a critical legal battleground.
- Enforcement of biosimilar patents continues to shape competitive dynamics.
- Court rulings will impact Hetero’s ability to market biosimilars before patent expiry.
- The outcome influences investment and R&D strategies in the biosimilar space.
FAQs
1. What patents does AbbVie assert in this case?
AbbVie claims infringement of U.S. Patent Nos. 8,916,157 and 9,982,149, covering formulation and method claims related to Humira.
2. How does prior art influence the validity of the patents?
Hetero argues that prior art references, including biosimilar patents from competitors, render the claims obvious, threatening patent validity.
3. What is the significance of the FDA review process?
Approval of Hetero’s biosimilar by the FDA could bypass patent defenses if the biosimilar gets regulatory clearance before patent expiry, but lawsuits can still delay market entry.
4. How long do patent disputes typically last in biotech?
Two to three years are common from filing to resolution, though complex cases may extend longer depending on legal strategies and motions.
5. Could this case lead to settlement or licensing?
Yes, companies often settle or license patents to avoid lengthy litigation and market delays, especially in high-revenue drugs like Humira.
Sources
- U.S. District Court District of Delaware. (2025). Complaint: AbbVie Inc. v. Hetero Labs Limited. https://ded.uscourts.gov
- U.S. Patent and Trademark Office. (2023). Patent filings related to Humira. https://uspto.gov
- Food and Drug Administration. (2023). Biosimilar approval process. https://fda.gov
- Industry reports on biosimilar patent litigation trends. (2022).
- Market analysis of Humira biosimilar launches. (2024).
